Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24939703 | 0.79 | CREBBP (0.39) | ALDH1A1LMNA | |
| SCHEMBL22601621 | 0.76 | LMNA (0.32) | LMNA | |
| SCHEMBL13644630 | 0.76 | GPBAR1 (0.30) | — | |
| SCHEMBL20766727 | 0.72 | KMT2A (0.42) | — | |
| SCHEMBL4400934 | 0.71 | CYP1B1 (0.34) | ALDH1A1LMNA | |
| SCHEMBL14493744 | 0.70 | SMN1; SMN2 (0.43) | ALDH1A1LMNA | |
| SCHEMBL20057288 | 0.69 | BRD4 (0.37) | ALDH1A1LMNA | |
| SCHEMBL11237508 | 0.68 | F2 (0.32) | — | |
| SCHEMBL4400947 | 0.68 | TTR (0.39) | ALDH1A1LMNA | |
| SCHEMBL13643878 | 0.67 | TTR (0.38) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793928-B1 | PROCESS FOR PURIFYING A SAMPLE OF H38C2 ANTIBODY | PFIZER (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9163227-B2 | Anti-diabetic compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2015-10-20 | — | — | US | disclosed |
| US-9163227-B2 | Anti-diabetic compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2015-10-20 | — | — | US | disclosed |
| US-8722622-B2 | FGF21 conjugates and anti-diabetic uses thereof | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2014-05-13 | — | — | US | disclosed |
| US-8722622-B2 | FGF21 conjugates and anti-diabetic uses thereof | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2014-05-13 | — | — | US | disclosed |
| WO-2013093720-A2 | ANTI-DIABETIC COMPOUNDS | PFIZER INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130164310-A1 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED | 2013-06-27 | — | — | US | disclosed |
| US-20130164310-A1 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED | 2013-06-27 | — | — | US | disclosed |
| US-20120282279-A1 | Anti-Diabetic Compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2012-11-08 | — | — | US | disclosed |
| WO-2012059873-A2 | ANTI-DIABETIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LTD. (IE) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282279-A1 | Anti-Diabetic Compounds | GLP1R, FGF2, FGFR1 | ALDH1A1 1416/4885LMNA 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.